About this Journal Submit a Manuscript Table of Contents

Signal Transduction Inhibitors as Promising Anticancer Agents

Call for Papers

Cancer is one of the leading causes of mortality worldwide accounting for more than 7.6 million deaths worldwide in 2008 according to WHO which are predicted to continue rising with an estimate of 13.1 million deaths in the year 2030. Cancer is a group of diseases sharing common features like unrestrictive growth, metastasis, and angiogenesis; however, the basic signal transduction pathways are deregulated to such an extent that every cancer case itself poses new challenges for the therapeutics. Better understanding of various signaling cascades involved in normal cellular processes gives us better insights about potential deregulated signal transduction pathways in cancer. Organ and tissue specific microenvironment is also dysregulated in tumorigenesis. Recent advances in cancer research have enabled the scientists to exploit better and novel druggable targets resulting in better efficacy of modern drugs. However, continuing research is required to tackle issues like acquisition of mutations and drug resistance by the cancer cells. A new avenue of development of drugs with multiple targets as well as combinatorial therapies has started yielding better drugs. In the present special issue our focus is on development of inhibitors for various cell signaling pathways targeting cancer.

The guest editors invite investigators to contribute original research articles as well as review articles that will stimulate the continuing efforts for understanding cancer signaling for development of better anticancer drugs. Potential topics include, but are not limited to:

  • Understanding of signal transduction alteration in cancer development
  • Experimental studies highlighting the role of various cell signaling molecules involved in carcinogenesis
  • Mechanistic studies involving better (novel) animal/cell culture models for signal transduction studies in cancer
  • Evaluation of synthetic and natural products as cell signaling inhibitors in cancer development, angiogenesis, and metastasis

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/pharmacology/stip/ according to the following timetable:

Manuscript DueFriday, 25 July 2014
First Round of ReviewsFriday, 17 October 2014
Publication DateFriday, 12 December 2014

Lead Guest Editor

  • Raj Kumar, Centre for Chemical and Pharmaceutical Sciences, Central University of Punjab, Bathinda, Punjab 151001, India

Guest Editors

  • Cedric D. Santos, Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania, 710 BRB-II/III, 421 Curie Boulevard, Philadelphia, PA 19104-6160, USA
  • Tarunveer S. Ahluwalia, The Novo Nordisk Foundation Centre for Basic Metabolic Research, Section of Metabolic Genetics, Faculty of Medical and Health Sciences, University of Copenhagen, Universitetsparken 1, DIKU Building, 2100 Copenhagen Ø, Denmark
  • Sandeep Singh, Centre for Genetic Diseases and Molecular Medicine, Central University of Punjab, Bathinda, Punjab 151001, India